Fierce Medtech Names Genesis Therapeutics a “Fierce 15” Company of 2023
BURLINGAME, Calif.–(BUSINESS WIRE)–Genesis Therapeutics, a company pioneering generative and predictive artificial intelligence (AI) technologies to develop breakthrough therapeutics for underserved patient populations, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medtech companies. The annual special report features the most innovative private companies in the industry.
Genesis has developed the field-leading AI platform for small molecule structure-based drug design, called Genesis Exploration of Molecular Space (GEMS), which leverages proprietary, physics-inspired generative and predictive AI methods to discover first-in-class and best-in-class molecules for challenging or previously undruggable targets. GEMS can generate novel drug-like molecules and make rapid and accurate predictions of key properties such as pose, potency, selectivity, and ADMET for highly challenging targets that lack pre-existing chemical matter as starting points for drug discovery.
To date, Genesis has applied GEMS to develop a pipeline of drug programs – both wholly owned and in external collaborations – across a range of therapeutic areas. Using proceeds from its $200M Series B raise in 2023, the company plans to further advance the GEMS platform, bring forward its pipeline into clinical development, and ambitiously expand its wholly owned pipeline including in new therapeutic areas.
“We are honored to receive this recognition from Fierce and be included among true innovators in AI and life sciences,” said Evan Feinberg, Ph.D., co-founder and CEO of Genesis. “We believe that with GEMS featuring ML models that are purpose-built to solve the most challenging yet rate-limiting aspects of drug discovery, our AI platform is a crucial catalyst for achieving our mission of developing treatments for diseases representing high unmet need. Being named a Fierce 15 company is testament that our team is yielding tangible results in developing AI technologies that generate transformative drugs for patients.”
“Every year we celebrate a few of the most innovative life sciences companies, whether they’re focused on helping clinicians reach, diagnose and treat the sick, or leveraging AI to develop the next scientific and medical breakthroughs,” said Conor Hale, senior editor of Fierce Medtech. “These companies exemplify the ability of the life sciences industry to turn cutting-edge ideas into meaningful outcomes.”
About Genesis Therapeutics
Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery.
The GEMS platform integrates deep learning-based predictive models, molecular simulations, and chemically aware language models. GEMS accelerates candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. Using GEMS’s unique advantages, the company has built an internal pipeline with multiple programs against targets that are data-poor and canonically undruggable. Genesis also has strategic collaborations with Lilly and Genentech.
To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.
About Fierce Medtech
Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. Top industry professionals rely on Fierce Medtech for an insider briefing on the day’s top stories.
Contacts
Investors:
Will McCarthy
Chief Operating Officer
will@genesistherapeutics.ai
Media:
Azeem Zeekrya
HDMZ
genesis.pr@hdmz.com
(312) 506-5244
